Gravity Analytica

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SPRY 12.18.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our SPRY Tweets

About Gravity Analytica

Recent Filings

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) --ARS Pharmaceuticals, Inc.(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 43^rdAnnual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 in San Francisco.

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma, will present on Wednesday, January 15, 2025, at 7:30 a.m. PT. Company management will also participate in one-on-one meetings with investors.

A live webcast of the presentation will be available in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializingneffy®2 mg (trade nameEURneffy®in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visitwww.ars-pharma.com.

ARS Investor Contacts:Justin ChakmaARS Pharmaceuticalsjustinc@ars-pharma.com

ARS Media Contact:Christy CurranSam Brown Inc.christycurran@sambrown.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com